Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 05, ...
Funding supports IND-enabling activities for Casma’s CSM-101, a first-in-class TRPML1 agonist targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., March ...
Lysosomal homeostasis is crucial to the metabolism of certain proteins and lipids that would otherwise accumulate, thus leading to cellular stress and pathology. This is common in diseases such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results